40 58

Cited 0 times in

One-Year Outcome of Multiple Blood-Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma

DC FieldValueLanguage
dc.contributor.author김명지-
dc.contributor.author박소희-
dc.contributor.author장원석-
dc.contributor.author장진우-
dc.contributor.author정현호-
dc.contributor.author최현석-
dc.date.accessioned2020-12-01T16:49:24Z-
dc.date.available2020-12-01T16:49:24Z-
dc.date.issued2020-09-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/179992-
dc.description.abstractIntroduction: To overcome the blood-brain barrier (BBB) which interferes with the effect of chemotherapeutic agents, we performed multiple disruptions of BBB (BBBD) with magnetic resonance-guided focused ultrasound on patients with glioblastoma (GBM) during standard adjuvant temozolomide (TMZ) chemotherapy [clinical trial registration no.NCT03712293 (clinicaltrials.gov)]. We report a 1-year follow-up result of BBBD with TMZ for GBM. Methods: From September 2018 to January 2019, six patients were enrolled (four men and two women, median age: 53 years, range: 50-67 years). Of the six patients, five underwent a total of six cycles of BBBD during standard TMZ adjuvant therapy. One patient underwent three cycles of BBBD but continued with TMZ chemotherapy. The 1-year follow-up results of these six patients were reviewed. Results: The mean follow-up duration was 15.17 ± 1.72 months. Two patients showed a recurrence of tumor at 11 and 16 months, respectively. One underwent surgery, and the other patient was restarted with TMZ chemotherapy due to the tumor location with a highly possibility of surgical complications. The survival rate up to 1 year was 100%, and the other four patients are on observation without recurrence. None of the six patients had immediate or delayed BBBD-related complications. Conclusion: Multiple BBBDs can be regarded as a safe procedure without long-term complications, and it seems to have some survival benefits. However, since TMZ partially crosses the BBB, a further extended study with large numbers would be needed to evaluate the benefits of BBBD resulting in an increase of TMZ concentration. This study opened a new therapeutic strategy for GBM by combining BBBD with a larger molecular agent.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherFrontiers Research Foundation-
dc.relation.isPartOfFRONTIERS IN ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleOne-Year Outcome of Multiple Blood-Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurosurgery (신경외과학교실)-
dc.contributor.googleauthorSo Hee Park-
dc.contributor.googleauthorMyung Ji Kim-
dc.contributor.googleauthorHyun Ho Jung-
dc.contributor.googleauthorWon Seok Chang-
dc.contributor.googleauthorHyun Seok Choi-
dc.contributor.googleauthorItay Rachmilevitch-
dc.contributor.googleauthorEyal Zadicario-
dc.contributor.googleauthorJin Woo Chang-
dc.identifier.doi10.3389/fonc.2020.01663-
dc.contributor.localIdA05897-
dc.contributor.localIdA05904-
dc.contributor.localIdA05904-
dc.contributor.localIdA03454-
dc.contributor.localIdA03454-
dc.contributor.localIdA03484-
dc.contributor.localIdA03484-
dc.contributor.localIdA03775-
dc.contributor.localIdA03775-
dc.contributor.localIdA04209-
dc.contributor.localIdA04209-
dc.relation.journalcodeJ03512-
dc.identifier.eissn2234-943X-
dc.identifier.pmid33014832-
dc.subject.keywordblood–brain barrier-
dc.subject.keywordfocused ultrasound-
dc.subject.keywordglioblastoma multiforme-
dc.subject.keywordmagnetic resonance images-
dc.subject.keywordprogression-free survival-
dc.contributor.alternativeNameKim, Myung Ji-
dc.contributor.affiliatedAuthor김명지-
dc.contributor.affiliatedAuthor박소희-
dc.contributor.affiliatedAuthor박소희-
dc.contributor.affiliatedAuthor장원석-
dc.contributor.affiliatedAuthor장원석-
dc.contributor.affiliatedAuthor장진우-
dc.contributor.affiliatedAuthor장진우-
dc.contributor.affiliatedAuthor정현호-
dc.contributor.affiliatedAuthor정현호-
dc.contributor.affiliatedAuthor최현석-
dc.contributor.affiliatedAuthor최현석-
dc.citation.volume10-
dc.citation.startPage1663-
dc.identifier.bibliographicCitationFRONTIERS IN ONCOLOGY, Vol.10 : 1663, 2020-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.